VGWCF - Valens GroWorks Corp.

Other OTC - Other OTC Delayed Price. Currency in USD
2.6090
+0.1502 (+6.11%)
As of 11:55AM EST. Market open.
Stock chart is not supported by your current browser
Previous Close2.4588
Open2.5250
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range2.4955 - 2.6800
52 Week Range0.8475 - 3.6600
Volume128,583
Avg. Volume202,348
Market Cap322.728M
Beta (3Y Monthly)3.36
PE Ratio (TTM)N/A
EPS (TTM)-0.1050
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Valens establishes operations in The Greater Toronto Area with the acquisition of a leading beverage company
    CNW Group

    Valens establishes operations in The Greater Toronto Area with the acquisition of a leading beverage company

    Valens establishes operations in The Greater Toronto Area with the acquisition of a leading beverage company

  • Benzinga

    Valens, BRNT Enter White Label Agreement To Launch A Line Of Vape Pens

    Valens GroWorks Corp. (TSXV: VGW) (OTC: VGWCF) said Wednesday it has entered into a white label agreement with BRNT Ltd to launch a line of cannabis vape pens in Canada. Per the agreement, Valens should supply cannabis extract, filing and distribution services for a line of BRNT-branded vape pens. The initial term of the agreement is set to two years during which Valens should produce a minimum of 2.2 million BRNT-branded vape pens.

  • BRNT Group Announces Multi-Year Partnership with Valens GroWorks Corp. to Launch a New Line of Cannabis Extract Vaporizers
    CNW Group

    BRNT Group Announces Multi-Year Partnership with Valens GroWorks Corp. to Launch a New Line of Cannabis Extract Vaporizers

    EDMONTON , Oct. 31, 2019 /CNW/ - BRNT Group is proud to announce its partnership with Valens GroWorks Corp. (TSXV:VGW) (VGWCF) (the "Company" or "Valens"), to bring Made By vaporizers, a line of single-source cannabis extract vaporizers with artfully designed hardware, to a Canadian audience.

  • Valens and BRNT Enter into Major White Label Deal with a Gross Revenue Potential to Valens of More Than $50 Million
    PR Newswire

    Valens and BRNT Enter into Major White Label Deal with a Gross Revenue Potential to Valens of More Than $50 Million

    KELOWNA, BC, Oct. 30, 2019 /PRNewswire/ - Valens GroWorks Corp. (TSXV:VGW) (VGWCF) (the "Company" or "Valens"), a vertically integrated provider of industry leading extraction products and services; including a diverse suite of extraction methodologies, next generation cannabinoid delivery formats and an ISO 17025 accredited analytical lab is pleased to announce a multi-year white label agreement (the "Agreement") with BRNT Ltd ("BRNT"), a leading, premium, cannabis ancillary company to launch a line of unique cannabis vape pens in Canada. Under the terms of the Agreement, Valens will provide high-quality cannabis extracts, filling services and national distribution of a line of custom-formulated BRNT-branded vape pens. The initial term of the Agreement will be for two years, with two successive one year renewal options, and relates to the production and sale of a guaranteed minimum of 2.2 million BRNT-branded vape pens, with the gross revenue potential to Valens under the Agreement of over $50 million in the first two years, all subject to final acceptance from provincial distributors, including of the proposed price per unit.

  • Benzinga

    Canadian Cannabis Extraction Execs Talk Tech, Staffing, Innovation

    Moderated by Mitch Osak, partner at MNP, the panel included experts from several Canadian brands. Everett Knight, the executive vice president of strategy and investments at Valens Groworks Corp (OTC: VGWCF), also discussed human capital.

  • Benzinga

    These Were The Companies Added And Removed From OTC Markets Indexes At The End Of Q3

    Most major cap-weighted indexes are rebalanced quarterly, semi-annually, or annually. This rebalancing consists of adding and removing securities based on market cap fluctuations throughout the quarter.  ...

  • Benzinga

    Valens CEO On Q3 Print: We're The Most Profitable Canadian Cannabis Company

    Valens GroWorks Corp. (TSX: VGW) (OTC: VGWCF) reported third-quarter revenue of $16.5 million Tuesday, an 87.1% quarter-over-quarter jump. “The performance in the third quarter is a clear representation of Valens’ commitment to quality, strategy and execution and is also driven by the continued ramp up in services with existing, industry-leading clients...as well as first-time revenues from new customers," CEO Tyler Robson told Benzinga.

  • Valens Reports Record Revenue, Adjusted EBITDA and Profitability for the Third Quarter of Fiscal 2019
    CNW Group

    Valens Reports Record Revenue, Adjusted EBITDA and Profitability for the Third Quarter of Fiscal 2019

    Net income of $5.9 million (or $0.05 per share basic and diluted) in the third quarter, compared to a net loss of $10.5 million (or a loss of $0.10 per share basic and diluted) in the second quarter of 2019. "We are extremely pleased with the roll-out of our business plan and the continued scale up in the Company's extraction operations which have allowed us to continue our aggressive quarter over quarter growth in volumes, revenue, adjusted EBITDA and net income." said Tyler Robson , CEO of Valens. "The Company's performance in the third quarter clearly demonstrates our industry leading technical capabilities, the quality of our products and the earnings power of our platform.

  • Newsfile

    Benzinga Announces: Valens GroWorks Corp. Presenting at the Cannabis Capital Conference in Chicago

    Chicago, Illinois--(Newsfile Corp. - October 15, 2019) - Valens GroWorks Corp. (TSXV: VGW) (OTCQX: VGWCF), will be presenting at the 5th Benzinga Cannabis Capital Conference in Chicago October 22-23 before an audience of well-vetted public and private companies, and an audience of fellow institutional, family office and accredited investors looking for the right opportunities in a crowded and volatile market. Investment opportunities abound. For more information and/or to register for the conference please visit: ...

  • 3 Cannabis Extraction Stocks Poised To Rally
    TipRanks

    3 Cannabis Extraction Stocks Poised To Rally

    As Canada heads towards Cannabis 2.0, the stock market will start looking towards companies that provide more value than pure dried cannabis cultivation output. Companies that offer high value services to the industry without the large capital investments required to build massive growing facilities will garner more investor appeal and higher stock valuations.The cannabis extractor space is just the area to watch going into 2020 as the companies become more valuable with Cannabis 2.0 products requiring more specialized capabilities from integrated extraction service providers. The sector is generally focused on bulk oil extracts now, but the move into beverages, edibles, vapes and concentrates will require more complex capabilities and facilities.The key here is that while pot has been grown illegally for centuries by various individuals and groups, the market for cannabis extracts is relatively untapped. Companies moving up the value chain should grab higher margins while not having to compete with illegal sources. The extraction of cannabis concentrates is a complex and potentially dangerous process and should only be performed by trained professionals providing a market advantage to the companies with these capabilities.Any company that can grab market share in this area and establish themselves as a leading provider of high-quality extraction services and product testing will reward shareholders. The future market has the potential to shift towards 75% oil based products according to Cowen Equity Research leaving the companies involved in the extraction and product development process as the potential future market leaders.We’ve delved into three small companies poised to profit from the demand for third party cannabis extraction services and the development of high-value add products:Valens GroWorks (VGWCF)One of the major players in the cannabis extraction business is Valens GroWorks with contracts with 5 of the top 10 cannabis companies in Canada. The company is building a large extraction facility with a target for 1,000,000 kg of annual throughput while having 240,000 kg in demand from customers for 2020.The company recently updated guidance for Q3 to revenues of $16 million to $17 million, up from only $8.8 million in the prior quarter. Valens GroWorks projects extracting 26,000 kg of cannabis and hemp biomass in the quarter ending in August with 50% of the extractions taking place in the last month.The company is in the process of moving annual processing capabilities from 425,000 kg of cannabis and hemp biomass to 1,000,000 kg by early 2020. In the process, the company forecasts reaching $218.1 million in 2021 revenues with over $100 million in EBITDA profits.Valens GroWorks generated a solid $2.0 million in EBITDA profits in the last quarter and another quarter of huge profits would push the stock higher in an industry where losses are very common now. The cannabis extraction company has the additional catalyst of listing on a major stock exchange in the future. With a fully diluted share count of 140 million shares, the stock is relatively cheap at a market cap of only $325 million.The stock is an incredible value of below 4x EBITDA targets for just a year out from where the market will start looking at 2021 estimates.Over the last three months, Valens GroWorks stock has received 3 Buy ratings. As a result, the stock has a ‘Strong Buy’ analyst consensus rating. These analysts believe (on average) that the cannabis stock has big upside potential of over 190% from the current share price. This would take Valens from $2.22 all the way to $6.47. (See Valens stock analysis on TipRanks)MediPharm Labs (MEDIF)The largest company in the space is MediPharm Labs with quarterly revenues of C$31.4 million. In the quarter ended June 30, the company generated C$7.7 million of EBITDA for an impressive 24% EBITDA margin.Similar to the industry, MediPharm Labs is in the process of expanding extraction capabilities. The company recently reached 300,000 kg of extraction capacity with the plans to increase annual capacity to 500,000 kg via the expansion of the facility at the Barrie, Ontario headquarters.The company already has medical cannabis concentrate supply deals in both Germany and Australia making for a global play without all of the high costs of having massive global operations. In addition, MediPharm Labs has at least four large contracts with the likes of Canopy Growth and Cronos Group.MediPharm recently closed a $75 million bought deal financing to provide the capital needed for expansion while operations are expected to generate significant EBITDA in the coming year. At $3, the stock has a market valuation of only $385 million.The extraction-service provider is without question a Wall Street favorite, considering TipRanks analytics indicate MediPharm as a Strong Buy. Out of 5 analysts polled in the last 3 months, all 5 are bullish on the stock. With a return potential of about 120%, the stock's consensus target price stands at $6.41. (See MediPharm stock analysis on TipRanks)Neptune Wellness Solutions (NEPT)Neptune Wellness Solutions is the wildcard in the sector after generating a large C$6.5 million loss in the last quarter on only C$4.4 million in revenues. The company has big cannabis extraction plans, but the current results are less than impressive with revenues actually declining from last FQ1 levels.The company recently bought SugarLeaf Labs and Forest Remedies LLC for $18 million in upfront payments and up to another $132 million in cash and stock over the next three years. The extraction capacity of SugarLeaf is expected to reach 1,500,000 kg of biomass by the end of 2019. In addition, Canada operations expanded in September from 30,000 kg of biomass processing capacity to 200,000 kg annually.Recent deals with both Tilray and The Green Organic Dutchman should quickly expand revenues. The company forecasts the existing facilities will provide for annual revenues of $450 million at only 50% capacity with EBITDA margins of 40%.The biggest hiccup with Neptune is the unknown financials and the eventual requirement to pay up to another $132 million for SugarLeaf while the company only has a cash balance of $39 million in July.Neptune has a listed market value of $340 million, but the highest risk due to the financial position and cash outlays for SugerLeaf while being the only stock in the group generating current losses. Even worse, the CFO is leaving.What do analysts say about this extraction-services provider? TipRanks analytics show two bullish analysts who rate the stock a Buy, and the average price target among the two stands at $8.62 -- a whopping 148% upside. (See NEPT stock analysis on TipRanks)

  • Valens to Hold Conference Call to Discuss Financial Results for the Third Quarter of Fiscal 2019
    CNW Group

    Valens to Hold Conference Call to Discuss Financial Results for the Third Quarter of Fiscal 2019

    Valens to Hold Conference Call to Discuss Financial Results for the Third Quarter of Fiscal 2019

  • Cannabis stocks rise for third straight day as vaping fears appear to ease
    MarketWatch

    Cannabis stocks rise for third straight day as vaping fears appear to ease

    Cannabis stocks rise for a third straight day Friday, buoyed by reports that vape sales are rebounding after being hit by the outbreak of a serious lung disease that experts say is directly tied to vaping.

  • Valens Announces Results of Annual General and Special Meeting of Shareholders
    PR Newswire

    Valens Announces Results of Annual General and Special Meeting of Shareholders

    KELOWNA, BC , Sept. 24, 2019 /PRNewswire/ -  Valens GroWorks Corp. (TSXV: VGW) (OTCQX: VGWCF)  (the " Company " or " Valens "), a vertically integrated provider of industry leading ...

  • Valens Receives Amended License from Health Canada Permitting Sales Directly to Provinces and Territories & Provides Operational Update
    PR Newswire

    Valens Receives Amended License from Health Canada Permitting Sales Directly to Provinces and Territories & Provides Operational Update

    Under the new license, Valens is now authorized to manufacture and supply oil products directly to provincial distributors and other authorized Canadian retail supply channels. Valens will immediately start leveraging this amended license to expand services provided to its white label manufacturing partners, delivering retail ready products including tinctures and gel caps.  The Company plans to further expand its retail ready product offerings to include vaporizer cartridges, beverages, topicals and other desired products as permitted by Health Canada.

  • Benzinga

    Valens GroWorks To Supply Shoppers Drug Mart With Cannabis Oil Products

    Valens GroWorks Corp. (TSXV: VGW) (OTC: VGWCF) said Monday it has signed a supply agreement with the Shoppers Drug Mart-owned medical cannabis e-commerce site Medical Cannabis by Shoppers for cannabis oil derivative products. Valens GroWorks Corp. is a vertically integrated cannabis company and the biggest third-party extraction company in Canada.

  • PR Newswire

    Cannabis Virtual Investor Conference Presentations Now Available for On-Demand Viewing

    Individual and institutional investors as well as advisors are invited to log-on to VirtualInvestorConferences.com to view the presentations NEW YORK , Sept. 16, 2019 /PRNewswire/ -- Virtual Investor Conferences ...

  • Valens Becomes First Third Party Processor to Enter Strategic Agreement with Shoppers Drug Mart to Supply Cannabis Oil Products
    PR Newswire

    Valens Becomes First Third Party Processor to Enter Strategic Agreement with Shoppers Drug Mart to Supply Cannabis Oil Products

    KELOWNA, BC , Sept. 16, 2019 /PRNewswire/ -  Valens GroWorks Corp. (TSXV: VGW) (OTC: VGWCF)  (the " Company " or " Valens "), a vertically integrated provider of industry leading extraction ...